Last reviewed · How we verify
NCT03534973: Caff2
Prevention of UV- Induced Apoptosis by Caffeine
NA trial testing Caffeine intake in Cataract in 20 participants. Status unknown.
1 December 2019
Quick facts
| Lead sponsor | Vienna Institute for Research in Ocular Surgery |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 20 |
| Start date | 17 April 2018 |
| Primary completion | 1 December 2019 |
| Estimated completion | 1 January 2020 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Caffeine intake
- No caffeine intake
Conditions studied
- Cataract — all drugs for Cataract →
Sponsor
Vienna Institute for Research in Ocular Surgery
Who can join
Adults 21 to 105, any sex, with Cataract. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Investigate if caffeine accumulation in human lens epithelial cells after oral caffeine intake is sufficient to prevent from experimental ultraviolet radiation induced apoptosis
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03534973
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Caffeine intake
Trials testing the same drug.
- NCT06561113 — The Effect of Turkish Coffee on Postural Control and Hand-eye Coordination in Young Adults · NA · completed
Other recruiting trials for Cataract
Currently open trials in the same condition.
- NCT07301385 — Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety a · NA · recruiting
- NCT07462000 — Aqueous Humor and Ocular Tissue Analysis in Glaucoma and Cataract · NA · recruiting
- NCT06891092 — Vivinex Impress XY1-EM vs RayOne EMV · NA · recruiting
- NCT07218796 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
- NCT07218783 — Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compar · Phase 3 · recruiting
Other Vienna Institute for Research in Ocular Surgery trials
Trials by the same sponsor.
- NCT07262021 — Visual Function of Enhanced Monofocal Intraocular Lenses · NA · not yet recruiting
- NCT06914817 — Brillouin Microscopy Used to Evaluate Corneal Mechanical Properties · NA · not yet recruiting
- NCT07297849 — Eyelid Closure in Keratometry · NA · recruiting
- NCT07390253 — Switch From 2mg Aflibercept to 8mg Aflibercept in Patients With Neovascular Age-related Macular Degeneration · active not recruiting
- NCT06607848 — Comparison of Two Non- Diffractive Extended Depth of Focus Intraocular Lenses · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03534973 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vienna Institute for Research in Ocular Surgery
- Last refreshed: 2 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03534973.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing